NASDAQ:PTLA - Portola Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$43.73 +1.74 (+4.14 %)
(As of 06/24/2018 04:00 PM ET)
Previous Close$43.73
Today's Range$41.67 - $44.25
52-Week Range$30.10 - $67.10
Volume3.17 million shs
Average Volume1.07 million shs
Market Capitalization$2.76 billion
P/E Ratio-9.09
Dividend YieldN/A
Beta1.5
Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers. It is also developing PRT2761, which is in Phase 2 for allergic conjunctivitis; and PCSK9 inhibitor in pre-clinical study for hypercholesterolemia. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Dermavant Sciences GmbH; and Ora, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Receive PTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTLA
CUSIPN/A
Phone650-246-7000

Debt

Debt-to-Equity Ratio0.35
Current Ratio7.59
Quick Ratio7.53

Price-To-Earnings

Trailing P/E Ratio-9.09
Forward P/E Ratio-8.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.55 million
Price / Sales127.64
Cash FlowN/A
Price / CashN/A
Book Value$5.36 per share
Price / Book8.16

Profitability

EPS (Most Recent Fiscal Year)($4.81)
Net Income$-286,090,000.00
Net Margins-1,364.89%
Return on Equity-109.35%
Return on Assets-65.49%

Miscellaneous

Employees252
Outstanding Shares65,820,000

The Truth About Cryptocurrencies

Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals Inc (NASDAQ:PTLA) posted its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.22) by $0.06. The biopharmaceutical company had revenue of $6.64 million for the quarter, compared to analysts' expectations of $3.20 million. Portola Pharmaceuticals had a negative return on equity of 109.35% and a negative net margin of 1,364.89%. Portola Pharmaceuticals's revenue for the quarter was up 29.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.74) EPS. View Portola Pharmaceuticals' Earnings History.

When is Portola Pharmaceuticals' next earnings date?

Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Portola Pharmaceuticals.

What price target have analysts set for PTLA?

7 analysts have issued 1-year target prices for Portola Pharmaceuticals' shares. Their forecasts range from $46.00 to $80.00. On average, they anticipate Portola Pharmaceuticals' stock price to reach $64.00 in the next twelve months. View Analyst Ratings for Portola Pharmaceuticals.

Who are some of Portola Pharmaceuticals' key competitors?

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the folowing people:
  • Mr. William Lis, CEO, Pres & Director (Age 54)
  • Ms. Mardi C. Dier, Interim Co-Pres, Exec. VP & CFO (Age 54)
  • Dr. John T. Curnutte, Interim Co-Pres & Exec. VP of R&D (Age 66)
  • Mr. Tao Fu, Chief Commercial & Bus. Officer and Exec. VP (Age 46)
  • Dr. John H. Lawrence III, M.D., Sr. VP & Chief Medical Officer (Age 60)

Has Portola Pharmaceuticals been receiving favorable news coverage?

Media coverage about PTLA stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Portola Pharmaceuticals earned a news impact score of 0.18 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.62 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Portola Pharmaceuticals' major shareholders?

Portola Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.09%), Kornitzer Capital Management Inc. KS (1.63%), Zevenbergen Capital Investments LLC (1.26%), Northern Trust Corp (1.12%), JPMorgan Chase & Co. (1.02%) and Pinnacle Associates Ltd. (0.65%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Henry Ward Wolff, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.

Which major investors are selling Portola Pharmaceuticals stock?

PTLA stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Royal Bank of Canada, Highland Capital Management LP, Allianz Asset Management GmbH, Allianz Asset Management GmbH, Artal Group S.A., Principal Financial Group Inc. and Principal Financial Group Inc.. Company insiders that have sold Portola Pharmaceuticals company stock in the last year include Henry Ward Wolff, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals.

Which major investors are buying Portola Pharmaceuticals stock?

PTLA stock was purchased by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, UBS Group AG, Sector Gamma AS, Russell Investments Group Ltd., Amundi Pioneer Asset Management Inc., Zevenbergen Capital Investments LLC, Delek Group Ltd. and RMB Capital Management LLC. View Insider Buying and Selling for Portola Pharmaceuticals.

How do I buy shares of Portola Pharmaceuticals?

Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of PTLA stock can currently be purchased for approximately $43.73.

How big of a company is Portola Pharmaceuticals?

Portola Pharmaceuticals has a market capitalization of $2.76 billion and generates $22.55 million in revenue each year. The biopharmaceutical company earns $-286,090,000.00 in net income (profit) each year or ($4.81) on an earnings per share basis. Portola Pharmaceuticals employs 252 workers across the globe.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]


MarketBeat Community Rating for Portola Pharmaceuticals (PTLA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  493
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe PTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.